ENDRA Life Sciences (NDRA) Net Equity Issued and Repurchased (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Net Equity Issued and Repurchased for 11 consecutive years, with $93937.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Equity Issued and Repurchased fell 89.04% year-over-year to $93937.0 in Q2 2026; TTM through Jun 2026 was $572709.0, a 89.04% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 77.31% from the prior year.
• Net Equity Issued and Repurchased was $93937.0 for Q2 2026 at ENDRA Life Sciences, down from $263747.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $7.5 million in Q2 2022 and troughed at $65559.0 in Q4 2025.
• A 5-year average of $1.6 million and a median of $692657.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased soared 542.48% in 2024 and tumbled 98.45% in 2025, its largest moves.
• Over 5 years, Net Equity Issued and Repurchased stood at $7.5 million in 2022, then sank by 91.3% to $656811.0 in 2023, then soared by 542.48% to $4.2 million in 2024, then plunged by 98.45% to $65559.0 in 2025, then surged by 43.29% to $93937.0 in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $93937.0 (Q2 2026), $263747.0 (Q1 2026), and $65559.0 (Q4 2025), per Business Quant data.